After successfully completing a project in RNA splicing in cancer this January, BioMed X and Merck continue their oncology collaboration to explore tumor immunogenicity enhancers.

Agreements Cement Strong Collaboration with Premier Cancer Center

Christopher Pagano Appointed Independent Director

Company founder Robert Coates becomes Executive Chairman

Debra Robinson, MBA, MPM, PMP, Sr. Director, Program and Alliance Management at Maverick Therapeutics, joins networking organization

Say YES to Hope and SMGlobal Catwalk make dreams come true for stage 4 cancer patients as they model during SMGlobal Dallas Revolution.

Delineation of the intra-tumor microenvironment in a dynamic, spatiotemporal setting is critical for investigating the activity and efficacy of candidate oncology drugs. The majority of solid cancers contain unorganized, highly complex microenvironments wherein a dysregulated phenotype impacts treatment outcomes at a personalized level.

World Stem Cell Summit and Phacilitate Leaders World to bring FOUR Meetings Together to Create Collaboration Needed to Deliver Global Cell and Gene Therapies!

ISCT confirmed as strategic partner for Phacilitate's trade mission to Asia, June 2018

Presented by Covance Chief Scientific Officer Steve Anderson, Ph.D., and Covance Global Leader, Precision Medicine and Head, Biomarker Solution Center, Suso Platero, Ph.D., this webinar will address the spectrum of immunotherapy development considerations and their implications for drug developers.

Global Market Study on Immuno-Oncology: Immune Checkpoint Inhibitors Segment Projected to be the Most Lucrative Segment by Therapy Type

Hanson Wade, the London-based life sciences knowledge services specialist, has launched IO Combination Trials Intelligence.

The discovery could improve treatments for autoimmune diseases and cancer